Dr Mikaila Jayaweera Bandara

  • Research Associate (Immunology)

Publications

List by: Type | Date

Jump to: 2020 | 2018 | 2017 | 2016
Number of items: 5.

2020

Fidler, S. et al. (2020) Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet, 395(10227), pp. 888-898. (doi: 10.1016/S0140-6736(19)32990-3) (PMID:32085823)

2018

Mok, H. P., Norton, N. J., Hirst, J. C., Fun, A., Bandara, M. , Wills, M. R. and Lever, A. M.L. (2018) No evidence of ongoing evolution in replication competent latent HIV-1 in a patient followed up for two years. Scientific Reports, 8, 2639. (doi: 10.1038/s41598-018-20682-w) (PMID:29422601) (PMCID:PMC5805784)

2017

Norton, N. J., Fun, A., Bandara, M. , Wills, M. R., Mok, H. P. and Lever, A. M.L. (2017) Innovations in the quantitative virus outgrowth assay and its use in clinical trials. Retrovirology, 14, 58. (doi: 10.1186/s12977-017-0381-2) (PMID:29268753) (PMCID:PMC5740843)

Bandara, M. , Skehel, J. M., Kadioglu, A., Collinson, I., Nobbs, A. H., Blocker, A. J. and Jenkinson, H. F. (2017) The accessory Sec system (SecY2A2) in Streptococcus pneumoniae is involved in export of pneumolysin toxin, adhesion and biofilm formation. Microbes and Infection, 19(7-8), pp. 402-412. (doi: 10.1016/j.micinf.2017.04.003) (PMID:28456649) (PMCID:PMC5526788)

2016

Bandara, M. , Corey, R. A., Martin, R., Skehel, J. M., Blocker, A. J., Jenkinson, H. F. and Collinson, I. (2016) Composition and activity of the non-canonical gram-positive SecY2 complex. Journal of Biological Chemistry, 291(41), pp. 21474-21484. (doi: 10.1074/jbc.m116.729806) (PMID:27551046) (PMCID:PMC5076819)

This list was generated on Mon Jan 17 10:51:20 2022 GMT.
Jump to: Articles
Number of items: 5.

Articles

Fidler, S. et al. (2020) Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial. Lancet, 395(10227), pp. 888-898. (doi: 10.1016/S0140-6736(19)32990-3) (PMID:32085823)

Mok, H. P., Norton, N. J., Hirst, J. C., Fun, A., Bandara, M. , Wills, M. R. and Lever, A. M.L. (2018) No evidence of ongoing evolution in replication competent latent HIV-1 in a patient followed up for two years. Scientific Reports, 8, 2639. (doi: 10.1038/s41598-018-20682-w) (PMID:29422601) (PMCID:PMC5805784)

Norton, N. J., Fun, A., Bandara, M. , Wills, M. R., Mok, H. P. and Lever, A. M.L. (2017) Innovations in the quantitative virus outgrowth assay and its use in clinical trials. Retrovirology, 14, 58. (doi: 10.1186/s12977-017-0381-2) (PMID:29268753) (PMCID:PMC5740843)

Bandara, M. , Skehel, J. M., Kadioglu, A., Collinson, I., Nobbs, A. H., Blocker, A. J. and Jenkinson, H. F. (2017) The accessory Sec system (SecY2A2) in Streptococcus pneumoniae is involved in export of pneumolysin toxin, adhesion and biofilm formation. Microbes and Infection, 19(7-8), pp. 402-412. (doi: 10.1016/j.micinf.2017.04.003) (PMID:28456649) (PMCID:PMC5526788)

Bandara, M. , Corey, R. A., Martin, R., Skehel, J. M., Blocker, A. J., Jenkinson, H. F. and Collinson, I. (2016) Composition and activity of the non-canonical gram-positive SecY2 complex. Journal of Biological Chemistry, 291(41), pp. 21474-21484. (doi: 10.1074/jbc.m116.729806) (PMID:27551046) (PMCID:PMC5076819)

This list was generated on Mon Jan 17 10:51:20 2022 GMT.